Factor IX gene therapy - Avigen

Drug Profile

Factor IX gene therapy - Avigen

Alternative Names: Coagulin B; Haemophilia B gene therapy

Latest Information Update: 07 Sep 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Avigen
  • Class Blood coagulation factors; Coagulants; Gene therapies
  • Mechanism of Action Factor IX stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia B

Highest Development Phases

  • Discontinued Haemophilia B

Most Recent Events

  • 27 Jun 2005 Discontinued - Phase-I for Haemophilia B in USA (IM)
  • 27 Jun 2005 Discontinued - Phase-I/II for Haemophilia B in USA (Intrahepatic)
  • 23 Jun 2005 Data presented at the 8th Annual Meeting of the American Society of Gene Therapy (ASGT-2005) have been added to the Haematological disorders pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top